InnoSer is an innovative, international, contract research organization focused on tailoring project plans that strategically adapt our services to support your specific project needs in drug discovery and preclinical drug development.
Low success rates in drug development have a profound societal and economic impact. Predictive quality in the preclinical phase is critical for the effective and safe compounds and the translation towards its use in humans during clinical trials.
InnoSer specializes in oncology, polycystic kidney disease, Alzheimer’s disease, Parkinson’s disease and cardiovascular diseases. Our expertise involves both in-vivo and in-vitro modeling in these areas. This offers our clients reliable and meaningful screening platforms that can be customized towards their specific needs.
We offer state-of-the-art methods and models, and maintain research efforts in collaboration with both academic and industrial partners to ensure our clients are offered a higher reliability in preclinical testing, thereby accelerating their drug research and lowering the attrition rate. Whether you require a global, full-service offering, a standalone service like Biostats or Safety Services, functional service provision of resources, or consulting, our teams of experts are here to help.